KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Average (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Equity Average readings, the most recent being $8.1 billion for Q1 2026.

  • On a quarterly basis, Equity Average rose 38.57% to $8.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $8.1 billion, a 38.57% increase, with the full-year FY2025 number at $6.6 billion, down 1.57% from a year prior.
  • Equity Average hit $8.1 billion in Q1 2026 for Teva Pharmaceutical Industries, up from $7.6 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $10.8 billion in Q1 2022 to a low of $5.8 billion in Q1 2025.
  • Median Equity Average over the past 5 years was $7.8 billion (2023), compared with a mean of $7.9 billion.
  • Biggest five-year swings in Equity Average: dropped 25.66% in 2025 and later skyrocketed 38.57% in 2026.
  • Teva Pharmaceutical Industries' Equity Average stood at $9.1 billion in 2022, then decreased by 14.31% to $7.8 billion in 2023, then fell by 24.17% to $5.9 billion in 2024, then grew by 28.91% to $7.6 billion in 2025, then increased by 6.45% to $8.1 billion in 2026.
  • The last three reported values for Equity Average were $8.1 billion (Q1 2026), $7.6 billion (Q4 2025), and $7.0 billion (Q3 2025) per Business Quant data.